Symbols / SLRX
SLRX Chart
About
Salarius Pharmaceuticals, Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufacture peptide conjugates targeting various unmet medical needs. The company focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. Salarius Pharmaceuticals, Inc. is based in Houston, Texas.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 4.92M |
| Enterprise Value | 114.55K | Income | -5.00M | Sales | — |
| Book/sh | 4.50 | Cash/sh | 0.82 | Dividend Yield | — |
| Payout | 0.00% | Employees | 2 | IPO | Jan 29, 2015 |
| P/E | — | Forward P/E | -0.09 | PEG | — |
| P/S | — | P/B | 0.19 | P/C | — |
| EV/EBITDA | -0.02 | EV/Sales | — | Quick Ratio | 2.60 |
| Current Ratio | 3.28 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -24.24 | EPS next Y | -9.17 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2024-11-14 16:00 | ROA | -69.91% |
| ROE | -139.55% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 5.86M |
| Shs Float | 5.82M | Short Float | 3.15% | Short Ratio | 0.31 |
| Short Interest | — | 52W High | 44.10 | 52W Low | 0.51 |
| Beta | 0.32 | Avg Volume | 3.84M | Volume | 5.96M |
| Target Price | — | Recom | None | Prev Close | $0.65 |
| Price | $0.84 | Change | 29.23% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.84
Latest analyst target
3. DCF / Fair value
$-8.65
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.84
Low
—
High
—
Mean
—
- Salarius Pharma (NASDAQ: SLRX) notes CapIQ errors, has ~$14M cash post Decoy merger - Stock Titan Wed, 19 Nov 2025 08
- DCOY - Finviz hu, 08 Jan 2026 10
- $SLRX stock is up 26% today. Here's what we see in our data. - Quiver Quantitative Wed, 07 Jan 2026 08
- Why Is Salarius Pharmaceuticals Stock (SLRX) Up 65% Today? - TipRanks Wed, 12 Nov 2025 08
- Salarius Pharmaceuticals (SLRX) Stock Jumps as $7M Offering Prices; Closing Expected November 12, 2025 Amid Decoy Therapeutics Merger - TechStock² Wed, 12 Nov 2025 08
- Day 7 of Loss Streak for Salarius Pharmaceuticals Stock with -75% Return (vs. -96% YTD) [11/11/2025] - Trefis ue, 11 Nov 2025 08
- Salarius Pharmaceuticals stock plunges after $7 million public offering By Investing.com - Investing.com Nigeria ue, 11 Nov 2025 08
- Why Did Salarius (SLRX) Shares Soar Over 23% After-Hours? - Benzinga ue, 11 Nov 2025 08
- Salarius (NASDAQ: SLRX), Decoy merge; $14M cash backs IMP3ACT peptide therapeutics - Stock Titan hu, 13 Nov 2025 08
- Salarius Pharma Stock Jumps After-Hours As Nasdaq Compliance Clears Path For Decoy Merger — Retail Bulls Bet On Breakout - Stocktwits Mon, 13 Oct 2025 07
- Salarius Pharmaceuticals Explorates Merger and Funding Moves - StocksToTrade Wed, 12 Nov 2025 08
- Why is Penny Stock Salarius Pharmaceuticals (SLRX) Up 182% Today? - TipRanks ue, 29 Jul 2025 07
- Salarius Pharma (NASDAQ: SLRX) prices offering at $1.50; $7M gross with warrants - Stock Titan ue, 11 Nov 2025 08
- Salarius Pharmaceuticals’ Recent Market Showdown - StocksToTrade ue, 29 Jul 2025 07
- Decoy Therapeutics pivots to next-gen antivirals for multi-virus threats - Stock Titan hu, 18 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 27 | 17 | — | Sale at price 0.64 per share. | HANISH ARNOLD C | Director | — | 2025-12-30 00:00:00 | D/I |
| 1 | 20000 | 16000 | — | Purchase at price 0.80 per share. | ROSENBLUM MARK J | Chief Financial Officer | — | 2025-11-20 00:00:00 | D |
| 2 | 5000 | 3740 | — | Purchase at price 0.75 per share. | HANISH ARNOLD C | Director | — | 2025-11-20 00:00:00 | I |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -5.73M | -12.88M | -14.12M | -12.84M |
| TotalUnusualItems | 0.00 | -8.85M | 44.69K | |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -8.85M | 44.69K | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -5.58M | -12.54M | -31.61M | -12.77M |
| ReconciledDepreciation | 4.42K | 10.05K | 6.68K | 19.18K |
| EBITDA | -5.73M | -12.88M | -22.97M | -12.79M |
| EBIT | -5.73M | -12.89M | -22.98M | -12.81M |
| NetInterestIncome | 158.54K | 352.25K | 218.73K | |
| InterestIncome | 158.54K | 352.25K | 218.73K | |
| NormalizedIncome | -5.58M | -12.54M | -22.76M | -12.81M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -5.58M | -12.54M | -31.61M | -12.77M |
| TotalExpenses | 5.73M | 12.89M | 22.98M | 12.81M |
| TotalOperatingIncomeAsReported | -31.84M | -12.81M | ||
| DilutedAverageShares | 64.15K | 27.20K | 17.70K | 13.79K |
| BasicAverageShares | 64.15K | 27.20K | 17.70K | 13.79K |
| DilutedEPS | -86.85 | -461.10 | -1.79K | -930.00 |
| BasicEPS | -86.85 | -461.10 | -1.79K | -930.00 |
| DilutedNIAvailtoComStockholders | -5.58M | -12.54M | -31.61M | -12.77M |
| NetIncomeCommonStockholders | -5.58M | -12.54M | -31.61M | -12.77M |
| OtherunderPreferredStockDividend | 0.00 | |||
| NetIncome | -5.58M | -12.54M | -31.61M | -12.77M |
| NetIncomeIncludingNoncontrollingInterests | -5.58M | -12.54M | -31.61M | -12.77M |
| NetIncomeContinuousOperations | -5.58M | -12.54M | -31.61M | -12.77M |
| PretaxIncome | -5.58M | -12.54M | -31.61M | -12.77M |
| OtherIncomeExpense | -8.85M | 44.69K | ||
| SpecialIncomeCharges | 0.00 | -8.87M | 0.00 | |
| ImpairmentOfCapitalAssets | 0.00 | 8.87M | 0.00 | |
| GainOnSaleOfSecurity | 14.45K | 44.69K | ||
| NetNonOperatingInterestIncomeExpense | 158.54K | 352.25K | 218.73K | |
| InterestIncomeNonOperating | 158.54K | 352.25K | 218.73K | |
| OperatingIncome | -5.73M | -12.89M | -22.98M | -12.81M |
| OperatingExpense | 5.73M | 12.89M | 22.98M | 12.81M |
| OtherOperatingExpenses | -1.84M | |||
| ResearchAndDevelopment | 770.03K | 7.17M | 15.84M | 8.55M |
| SellingGeneralAndAdministration | 4.96M | 5.72M | 7.14M | 6.10M |
| GeneralAndAdministrativeExpense | 4.96M | 5.72M | 7.14M | 6.10M |
| OtherGandA | 4.96M | 5.72M | 7.14M | 6.10M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 96.08K | 32.82K | 18.80K | 15.08K |
| ShareIssued | 96.08K | 32.82K | 18.80K | 15.08K |
| TotalDebt | 221.87K | 289.64K | ||
| TangibleBookValue | 1.51M | 5.29M | 10.38M | 29.86M |
| InvestedCapital | 1.73M | 5.58M | 10.38M | 38.72M |
| WorkingCapital | 1.48M | 5.22M | 10.25M | 28.05M |
| NetTangibleAssets | 1.51M | 5.29M | 10.38M | 29.86M |
| CommonStockEquity | 1.51M | 5.29M | 10.38M | 38.72M |
| TotalCapitalization | 1.51M | 5.29M | 10.38M | 38.72M |
| TotalEquityGrossMinorityInterest | 1.51M | 5.29M | 10.38M | 38.72M |
| StockholdersEquity | 1.51M | 5.29M | 10.38M | 38.72M |
| RetainedEarnings | -81.92M | -76.35M | -63.81M | -32.20M |
| AdditionalPaidInCapital | 83.44M | 81.64M | 74.19M | 70.92M |
| CapitalStock | 144.00 | 49.00 | 225.00 | 181.00 |
| CommonStock | 144.00 | 49.00 | 225.00 | 181.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 1.51M | 1.30M | 4.27M | 2.11M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentLiabilities | 1.51M | 1.30M | 4.27M | 2.11M |
| OtherCurrentLiabilities | 14.52K | |||
| CurrentDebtAndCapitalLeaseObligation | 221.87K | 289.64K | ||
| CurrentDebt | 221.87K | 289.64K | ||
| CurrentNotesPayable | 221.87K | 289.64K | 0.00 | 0.00 |
| PayablesAndAccruedExpenses | 1.29M | 1.01M | 4.27M | 2.11M |
| CurrentAccruedExpenses | 352.42K | 406.75K | 1.41M | 567.79K |
| Payables | 936.99K | 602.85K | 2.86M | 1.54M |
| AccountsPayable | 936.99K | 602.85K | 2.86M | 1.54M |
| TotalAssets | 3.02M | 6.59M | 14.65M | 40.83M |
| TotalNonCurrentAssets | 35.41K | 66.85K | 130.50K | 10.67M |
| OtherNonCurrentAssets | 35.41K | 66.85K | 130.50K | 193.87K |
| NonCurrentAccountsReceivable | 1.61M | |||
| GoodwillAndOtherIntangibleAssets | 0.00 | 8.87M | ||
| Goodwill | 0.00 | 8.87M | ||
| NetPPE | 7.88K | |||
| CurrentAssets | 2.99M | 6.52M | 14.52M | 30.16M |
| OtherCurrentAssets | 43.67K | 151.27K | 792.19K | 851.66K |
| CurrentDeferredAssets | 221.58K | 0.00 | ||
| PrepaidAssets | 287.79K | 468.50K | 11.19K | 97.56K |
| Receivables | 0.00 | 1.61M | 0.00 | |
| OtherReceivables | 1.61M | |||
| CashCashEquivalentsAndShortTermInvestments | 2.43M | 5.90M | 12.11M | 29.21M |
| CashAndCashEquivalents | 2.43M | 5.90M | 12.11M | 29.21M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -4.53M | -12.85M | -19.10M | -10.20M |
| RepaymentOfDebt | -466.50K | -280.92K | 0.00 | -477.03K |
| IssuanceOfCapitalStock | 1.53M | 6.92M | 1.99M | 27.29M |
| CapitalExpenditure | -1.50M | |||
| InterestPaidSupplementalData | 10.64K | 14.75K | 0.00 | 1.47K |
| EndCashPosition | 2.43M | 5.90M | 12.11M | 29.21M |
| BeginningCashPosition | 5.90M | 12.11M | 29.21M | 11.12M |
| ChangesInCash | -3.47M | -6.21M | -17.11M | 18.10M |
| FinancingCashFlow | 1.06M | 6.64M | 1.99M | 28.30M |
| CashFlowFromContinuingFinancingActivities | 1.06M | 6.64M | 1.99M | 28.30M |
| ProceedsFromStockOptionExercised | 0.00 | 1.49M | ||
| NetCommonStockIssuance | 1.53M | 6.92M | 1.99M | 27.29M |
| CommonStockIssuance | 1.53M | 6.92M | 1.99M | 27.29M |
| NetIssuancePaymentsOfDebt | -466.50K | -280.92K | 0.00 | -477.03K |
| NetShortTermDebtIssuance | -466.50K | -280.92K | 0.00 | -477.03K |
| ShortTermDebtPayments | -466.50K | -280.92K | 0.00 | -477.03K |
| NetLongTermDebtIssuance | -477.03K | |||
| LongTermDebtPayments | -477.03K | |||
| InvestingCashFlow | 0.00 | -1.50M | 0.00 | |
| CashFlowFromContinuingInvestingActivities | 0.00 | -1.50M | 0.00 | |
| NetIntangiblesPurchaseAndSale | 0.00 | -1.50M | 0.00 | |
| PurchaseOfIntangibles | 0.00 | -1.50M | 0.00 | |
| NetPPEPurchaseAndSale | 0.00 | |||
| PurchaseOfPPE | 0.00 | |||
| OperatingCashFlow | -4.53M | -12.85M | -17.60M | -10.20M |
| CashFlowFromContinuingOperatingActivities | -4.53M | -12.85M | -17.60M | -10.20M |
| ChangeInWorkingCapital | 772.29K | -968.33K | 2.37M | 2.03M |
| ChangeInPayablesAndAccruedExpense | 279.81K | -3.26M | 2.17M | -140.53K |
| ChangeInAccruedExpense | -54.33K | -1.00M | 854.53K | 170.13K |
| ChangeInPayable | 334.14K | -2.26M | 1.31M | -310.66K |
| ChangeInAccountPayable | 334.14K | -2.26M | 1.31M | -310.66K |
| ChangeInPrepaidAssets | 492.47K | 807.77K | 202.54K | -70.47K |
| ChangeInReceivables | 0.00 | 1.48M | 0.00 | 2.25M |
| OtherNonCashItems | 1.99M | |||
| StockBasedCompensation | 273.73K | 524.84K | 796.80K | 559.04K |
| AssetImpairmentCharge | 0.00 | 130.00K | 8.87M | 0.00 |
| DepreciationAmortizationDepletion | 4.42K | 10.05K | 6.68K | 19.18K |
| DepreciationAndAmortization | 4.42K | 10.05K | 6.68K | 19.18K |
| Depreciation | 4.42K | 10.05K | 6.68K | |
| OperatingGainsLosses | -14.45K | -44.69K | ||
| GainLossOnInvestmentSecurities | -14.45K | -44.69K | ||
| NetIncomeFromContinuingOperations | -5.58M | -12.54M | -31.61M | -12.77M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for SLRX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|